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A B S T R A C T   
APDS2 is caused by mutations in PIK3R1 gene resulting in constitutive PI3Kδ activation. PI3Kδ is predominantly expressed in leukocytes and plays critical roles in 
regulating immune responses. Here we first derived fibroblast primary cells from a skin biopsy of a patient carrying a heterozygous single T deletion in intron 11 of 
the PIK3R1 gene. We next present the derivation of an induced pluripotent stem cell (iPS) line using a non-integrative reprogramming technology. Pluripotent-related 
hallmarks are further shown, including: iPSCs self-renewal and expression of pluripotent and differentiation markers after in vitro differentiation towards embryonic 
germ layers, assessed by RT-PCR and immunofluorescence.   
Resource Table:  
Unique stem cell line 
identifier 
CVTTHi001-A 
Alternative name(s) of 
stem cell line 
Not applicable 
Institution Basque Centre for Blood Transfusion and Human Tissues 
(CVTTH), Osakidetza, Biocruces Bizkaia Health 
Research Institute 
Contact information of 
distributor 
Cristina Eguizabal Argaiz cristina. 
eguizabalargaiz@osakidetza.eus 
Type of cell line iPSC 
Origin Human fibroblast 
Additional origin info 22-years-old caucasian male 
Cell Source Fibroblast 
Clonality Clonal 




Transgene free (Cytotune™ iPS 2.0 Sendai 
reprogramming kit) 
Genetic Modification YES 
Type of Modification Hereditary 
Associated disease Activated phosphoinositide 3-kinase δ syndrome 2 
(APDS2) 
Gene/locus PIK3R1/chr 5q13.1 
Method of modification N/A 
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Cell line repository/bank 
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Fig.1. Characterization of APDS2 fibroblast-derived hiPS cell line.  
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(continued ) 
hPSCreg repository https://hpscreg. 
eu/cell-line/CVTTHi001-A 
Ethical approval The study was approved by the Basque Committee of 
Ethics and Clinical Research (Spain). Approval number 
PI2014206.   
1. Resource utility 
The derivation and characterization of a fibroblast-derived iPS cell 
line from a patient with APDS2 represents an unprecedented cell culture 
system to model and study APDS2-related clinical pathology. Further-
more, APDS2 iPSCs may open the door for the development of new 
treatments, representing a unique source as drug-screening platform and 
a model system for genome editing technology. 
2. Resource details 
The APDS2 primary immunodeficiency (PID), also called “p110δ- 
activating mutations causing senescent T cells, lymphadenopathy and 
immunodeficiency (PASLI-R1)” is caused by mutations in the gene that 
encodes the regulatory subunit of the heterodimer PI3K, a class IA 
complex. Two subunits compose class IA PI3K molecules: the catalytic 
subunit (p110α, p110β or p110γ) and the regulatory subunit (p85α, 
p55α, p50α, p85β or p55γ) encoded by the PIK3CD and the PIK3R1 
genes, respectively. The stability, cellular localization and function of 
p110 are regulated by the binding of any of the regulatory subunits. The 
expression of catalytic subunit p110γ is restricted mainly to leukocytes 
and p85α is the predominant regulatory subunit in lymphocytes (Elkaim 
et al., 2016). Several autosomal dominant mutations in a splice donor 
site of PIK3R1 gene resulting in an in-frame-skipping of exon 11 (coding 
exon 10) can cause APDS2 (Michalovich and Nejentsev, 2018). 
In this study, a human iPSC-line was established from primary fi-
broblasts isolated from a skin biopsy of a 22-years-old patient carrying a 
heterozygous single-nucleotide T deletion at position + 2 (c.1425 +
2delT) of the PIK3R1 gene splice donor site. This deletion results in the 
generation of a shorten transcript demonstrated by mRNA analysis by 
RT-PCR (data not shown), and consequently in a reduced regulatory 
subunit protein that lacks coding exon 10 (p.434-475del). 
Primary fibroblast cell cultures from ADPS2 patient (Fig. 1A) were 
induced to pluripotency using the non-integrating CytoTune-iPS 2.0 
Sendai Reprogramming kit (Invitrogene#A16517) containing Oct-4, 
Klf4, Sox-2 and c-Myc pluripotency transcription factors following the 
manufacturer’s instructions. The resulting APDS2-iPSC line (registered 
as CVTTHi001-A at the Human Pluripotent Stem Cell Registry, 
http://hPSCreg.eu) grew exhibiting the typical colony shape 
morphology (Fig. 1B). After some culture passages using mechanical 
disaggregation, expression of pluripotent genes was assessed by RT-PCR. 
As shown in Fig. 1C, exogenous transgene expression was silenced in 
APDS2-iPSC line while expression of endogenous pluripotent genes was 
detected (Fig. 1D) collectively demonstrating that the pluripotent state 
was not transitory. Assessment of mycoplasma amplification was nega-
tive (MinervaBiolabs#111050) (Fig. 1E). APDS2-iPSC line was assayed 
for the detection of protein expression for the transcription factors Oct- 
3/4, Nanog and Sox-2, and the surface markers Tra-1-81, SSEA-4 by 
immunofluorescence and flow cytometry analysis (Fig. 1F, G). More-
over, APDS2-iPSC line was further differentiated towards the three germ 
layers of the embryo following the manufacturer’s instructions of the 
STEMDiff kit (STEMCEL#05230). After differentiation induction, 
immunofluorescence analysis showed the detection of markers of 
endoderm, mesoderm and ectoderm fates as indicated in Fig. 1H, 
corroborating the inherent capacity of APDS2-iPSC line to differentiate 
in vitro. Sanger sequencing was used to further verify the detection of the 
heterozygous single-nucleotide T deletion at position +2 in c.1425 of the 
PIK3R1 gene (Table1, Fig. 1I). Karyotype analysis further confirmed the 
absence of major chromosomal aberrations in APDS2-iPSC line (Fig. 1J). 
Genotype of HLA (human leukocyte antigen) genes of APDS2-iPSC line 
are shown in Fig. 1K. All in all our approach sufficed for the generation 
of ADPS2 iPSC-line representing an affordable cell source to further 
study APDS2 etiology and pathology. Identity of donor fibroblasts and 
its derived iPSC line was tested by STR analysis (Supplementary file 1). 
3. Materials and methods 
3.1. Reprogramming and maintenance of the ADPS2 iPSC-line 
The minced patient skin biopsy was treated overnight at 37 ◦C with 
7500U of collagenase IV (LifeTechnologies#17104019) in 5 mL of 
DMEM (ThermoFisher#11965-092) supplemented with 10% FBS 
(ThermoFisher#10270-106), 1 mM Glutamax (Life-
Technologies#35050-038) and 50 U/mL of penicillin/streptomycin 
(LifeTechnologies#15140-122) [DMEM-FBS]. Following overnight 
collagenase treatment, the suspension was filtered through a 40 µm cell 
strainer and washed two times with DMEM-FBS medium. Fibroblast 
were left to grow into 10 cm culture dishes until 80% confluence and 
further expanded in DMEM-FBS medium. Reprogramming was per-
formed following the manufacturer’s instructions of the CytoTune-iPS 
Table 1 
Characterization and validation.  
Classification Test Result Data 
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Fig. 1 panel G 





Fig. 1 panel J 
Identity STR analysis Performed Supplementary 
file 1 (“STR 
analysis”) 
STR analysis 16 sites tested, 16 
sites matched 





Sanger Sequencing Heterozygous 
single nucleotide 
deletion (T) 
Fig. 1 panel I 





Mycoplasma Samples tested 
negative by PCR 
Fig. 1 panel E 
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potential 










Fig. 1 panel H 
Donor screening 
(OPTIONAL) 










HLA tissue typing HLA typed Class I 
and Class II 
Fig. 1 panel K  
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2.0 Sendai Reprogramming kit (Invitrogene#A16517). Cells were 
transduced at 30–60% confluence with viral particles with MOIs (mul-
tiplicity of infection) of KOS (Klf4, Oct-4 and Sox-2), hc-Myc and hKlf4 
of 5, 5 and 3 respectively. At day 7, cells were seeded in vitronectin- 
(Gibco#A31804) coated 6-well-plates at different dilutions (25.000 to 
300.000 cells) and cultured with Essential 8 Medium (Gib-
co#A1517001). Undifferentiated ADPS2-derived colonies were trans-
ferred onto vitronectin-coated culture dishes at day 18 of the 
reprogramming process. Five ADPS2-derived iPSC lines were passaged 
and amplified by mechanical dissection of undifferentiated fragments 
and transferred to freshly vitronectin-coated dishes for the different 
assays detailed hereafter. 
3.2. RT-PCR 
Total RNA was extracted using RNAqueous Micro Kit (Ambio-
n#AM1931). Following DNase treatment, RNA was retrotranscribed to 
cDNA using Super Script VILO kit (Invitrogen#11754050). RT-PCR was 
performed using primers for amplification of pluripotent and reprog-
ramming genes as indicated in Table 2. Primer sequences for pluripo-
tency markers and β-Actin were obtained from Cabrera et al. (2015) and 
Yang et al. (2015) respectively. 
3.3. Immunofluorescence 
ADPS2 colonies grown at 80% of confluence were fixed in 4% 
paraformaldehyde for 30 min at room temperature (RT) and washed 3 
times with 1X Tris-Buffered Saline (TBS) (50 mM Tris-Cl, pH 7.6; 150 
mM NaCl) for 5 min. Permeabilization and blocking was performed with 
TBS-T [TBS 1X + 0.5% Triton X-100 (Sidgma-Aldrich#9002-93-1)] with 
6% of donkey serum (Millipore#S30-100ML) for 30 min at RT. Primary 
antibodies were incubated overnight (Oct-3/4, Sox-2, SSEA-4, Nanog, 
Tra-1-81) or during 48 h (AFP, FoxA2, GFAP, Tuj1, ASMA, Sox9) at 4 ◦C. 
After three washes with 1X TBS, corresponding secondary antibodies 
were added for 2 h at 37 ◦C. Nuclei were counterstained with 0.1 µg/mL 
DAPI (LifeTechnologies#D21490). Images were taken with 20X objec-
tive of the Leica Microsystems DMi8 inverted microscope. 
3.4. Sequencing 
Primers were designed 200–250 nucleotides away from the deletion. 
Due to a high concentration of adenosines and thymidines in the 
sequence of interest, the forward primer was modified in its 5′ end by the 
addition of a 4-nucleotide adapter (shown in bold in Table 2). Following 
DNA isolation, PCR-amplified DNA fragments were sequenced by 
Eurofins Genomics Company. 
Table 2 
Reagents details.  
Antibodies used for immunocytochemistry/flow-cytometry  
Antibody Dilution Company Cat # and RRID 
Pluripotency Rabbit anti-Oct-3/4 1:25 Santa Cruz Biotechnology Cat# sc 9081, RRID:AB_2167703 
Pluripotency Mouse anti-Oct-3/4 1:25 Santa Cruz Biotechnology Cat# sc-5279, RRID:AB_628051 
Pluripotency Mouse anti-SSEA4 1:03 Hybridoma Bank Cat# MC-813-70, RRID:AB_528477 
Pluripotency Goat anti-Sox-2 1:25 Santa Cruz Biotechnology Cat# sc-17320, RRID:AB_2286684 
Pluripotency Goat anti-Nanog 1:25 R&D Systems Cat# AF1997, RRID:AB_355097 
Pluripotency Mouse anti -Tra-1-81 1: 200 Millipore Cat# MAB4381, RRID:AB_177638 
Differentiation (Endoderm) Goat anti-FoxA2 1:25 R&D Systems Cat# AF2400, RRID:AB_2294104 
Differentiation (Ectoderm) Mouse anti-Tuj1 1:500 Covance Cat# MMS-435, RRID:AB_2313773 
Differentiation (Ectoderm) Rabbit anti-GFAP 1:1000 Abcam. Cat# ab7260, RRID:AB_305808 
Differentiation (Mesoderm) Mouse anti-ASMA 1:400 Sigma-Aldrich Cat# A5228, RRID:AB_262054 
Differentiation (Mesoderm) Rabbit anti-Sox9 1:300 Sigma-Aldrich Cat# AB5535, RRID:AB_223976 
Pluripotency Alexa Fluor 488 donkey anti-goat IgG 1:200 ThermoFisher Scientific Cat# A11055, RRID:AB_2534102 
Pluripotency Alexa Fluor 546 donkey anti-mouse IgG 1:200 ThermoFisher Scientific Cat# A10036, RRID:AB_2534012 
Pluripotency/Differentiation Alexa Fluor 488 donkey anti-rabbit IgG 1:200 ThermoFisher Scientific Cat# A21206, RRID:AB_2535792 
Pluripotency/Differentiation Alexa Fluor 488 donkey anti-mouse IgG 1:200 ThermoFisher Scientific Cat# R37114, RRID:AB_2556542 
Pluripotency/Differentiation Alexa Fluor 546 donkey anti-goat IgG 1:200 ThermoFisher Scientific Cat# A11056, RRID:AB_142628 
Pluripotency Cy™3 AffiniPure donkey anti-mouse IgM 1:200 Jackson ImmunoResearch Cat# 715-165-140, RRID:AB_2340812 
Differentiation Alexa Fluor 546 donkey anti-rabbit IgG 1:200 ThermoFisher Scientific Cat# A10040, RRID:AB_2534016 
Pluripotency (flow cytometry) PE Mouse anit-SSEA-4 20 μl BD Biosciences Cat# 560128, RRID: AB_1645533  
Primers  
Target Forward/Reverse primer (5′-3′) 
Virus detection marker 
RT-PCR 
SeV (181 bp) GGATCACTAGGTGATATCGAGC / ACCAGACAAGAGTTTAAGAGATATGTATC 
Virus detection marker 
RT-PCR 
KOS (528 bp) ATGCACCGCTACGACGTGAGCGC / ACCTTGACAATCCTGATGTGG 
Virus detection marker 
RT-PCR 
Klf4 (410 bp) TTCCTGCATGCCAGAGGAGCCC / AATGTATCGAAGGTGCTCAA 
Virus detection marker 
RT-PCR 
c-Myc (532 bp) TAACTGACTAGCAGGCTTGTCG / TCCACATACAGTCCTGGATGATGATG 
Pluripotency marker 
RT-PCR 
Oct-4 (144 bp) GACAGGGGGAGGGGAGGAGCTAGG / CTTCCCTCCAACCAGTTGCCCCAAAC 
Pluripotency marker 
RT-PCR 
Sox-2 (151 bp) GGGAAATGGGAGGGGTGCAAAAGAGG / TTGCGTGAGTGTGGATGGGATTGGTG 
Pluripotency marker 
RT-PCR 
Klf4 (397 bp) ACGATCGTGGCCCCGGAAAAGGACC / TGATTGTAGTGCTTTCTGGCTGGGCTCC 
Pluripotency marker 
RT-PCR 
Nanog (343 bp) CAGCCCCGATTCTTCCACCAGTCCC / CGGAAGATTCCCAGTCGGGTTCACC 
Housekeeping gene 
RT-PCR 
β-Actin (194 bp) TCCCTGGAGAAGAGCTACGA / AGCACTGTGTTGGCGTACAG 
Deletion detection 
Sequencing 
PIK3R1 (469 bp) CTAGGATGTTTCCATGTCAGC / GAAACTCAGTGACTGCTTCAG  
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3.5. Karyotype 
Karyotype analysis was performed on iPSC cells in passage 24 by G- 
banded metaphase spreads that were prepared according to standard 
protocol of the Genetic Unit of Hospital de Basurto (Spain). Twenty 
metaphases images were taken and processed with GSL 120 Leica 
Microsystems. 
3.6. Mycoplasma detection 
Mycoplasma detection was performed with over-weekend cell cul-
ture medium following the protocol of the mycoplasma detection kit 
(MinervaBiolabs#11-1050). 
3.7. STR analysis 
Genetic identity of CVTTH001-A was determined by profiling of STR 
loci using the AmpFℓSTR™ Identifiler™ Plus PCR Amplification Kit 
(AppliedBiosystems#4427368) by the Genomic Platform of CIC bio-
GUNE (Spain). 
3.8. Flow cytometry 
Cells were detached using 0.5 mM EDTA and assessed for viability 
(Invitrogen#L34975) and SSEA-4 expression. 
3.9. HLA characterization 
HLA determination was performed in CVTTH (Galdakao, Spain) 
using next generation sequencing. 
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